메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 28, Issue 4, 2010, Pages
How should we prevent hematologic relapse of acute promyelocytic leukemia?
Author keywords

[No Author keywords available]
Indexed keywords

CYTARABINE; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;
EID: 77449158570     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.9995     Document Type: Letter
Times cited : (3)
References (5)
  • 1
    • 68949137224 scopus 로고    scopus 로고
    • Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    • Grimwade D, Jovanovic JV, Hills RK, et al: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3650-3658
    • Grimwade, D.1    Jovanovic, J.V.2    Hills, R.K.3
  • 2
    • 0032147033 scopus 로고    scopus 로고
    • Early detection of relapse by prospective reverse transcriptase- polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
    • Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784-789, 1998
    • (1998) Blood , vol.92 , pp. 784-789
    • Diverio, D.1    Rossi, V.2    Avvisati, G.3
  • 3
    • 59149103429 scopus 로고    scopus 로고
    • Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial
    • Burnett AK, Hills RK, Grimwade D, et al: Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood 110:181a, 2007 (suppl)
    • (2007) Blood , vol.110 , Issue.SUPPL.
    • Burnett, A.K.1    Hills, R.K.2    Grimwade, D.3
  • 4
    • 0033564337 scopus 로고    scopus 로고
    • Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans-retinoic acid: Results of the randomized MRC trial
    • Burnett AK, Grimwade D, Solomon E, et al: Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans-retinoic acid: Results of the randomized MRC trial. Blood 93:4131-4143, 1999
    • (1999) Blood , vol.93 , pp. 4131-4143
    • Burnett, A.K.1    Grimwade, D.2    Solomon, E.3
  • 5
    • 66849103735 scopus 로고    scopus 로고
    • Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: The European APL Group experience
    • Kelaidi C, Chevret S, De Botton S, et al: Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: The European APL Group experience. J Clin Oncol 27:2668-2676, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2668-2676
    • Kelaidi, C.1    Chevret, S.2    De Botton, S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.